Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN261201200031I
Award Date
9/24/12
Last Date to Order
9/23/19
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
2
Activity
4
Contract IDVs
Contract Awards
13
Transactions
8
Price Lists
Opportunity Stack
1
Federal Agency
National Cancer Institute
Awardee
University Of Arizona
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN12 - Health R&D Services; Health Care Services; Applied Research
Federal Contract Vehicle
Cancer Prevention Agent Development Program 2012-2017
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Cancer Prevention Agent Development Program 2012-2017
Master IDIQ
HHSN261201200031I
Indefinite Delivery Contract
13
Federal Contract Awards
Description
Update #1
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Posted 9/21/12, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00007
EO14042-CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Other Administrative Action
$0
6/17/22
P00006
EO14042-CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Other Administrative Action
$0
11/18/21
5
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Exercise an Option
$0
8/30/18
4
CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Exercise an Option
$0
8/11/17
3
OTHER FUNCTIONS: CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Other Administrative Action
$0
1/13/17
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN261201200031I-HHSN26100009
- A PROSPECTIVE, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, PHASE IIA TRIAL OF A NONAVALENT PROPHYLACTIC HPV VACCINE TO ASSESS IMMUNOGENICITY OF A PRIME AND DEFERRED-BOOSTER DOSING SCHEDULE AMONG 9-12 YEAR OLD GIRLS
University Of Arizona
$2.8m
9/1/15
6/30/23
12/22/22
Delivery Order HHSN261201200031I-HHSN26100008
M4OC-PREVENT: METFORMIN FOR ORAL CANCER PREVENTION
University Of Arizona
$813.0k
9/1/15
8/31/21
8/19/22
Delivery Order HHSN261201200031I-HHSN26100001
OTHER FUNCTIONS: CORE INFRASTRUCTURE SUPPORT FOR CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH.
University Of Arizona
$186.9k
9/24/12
9/23/13
9/29/16
Delivery Order HHSN261201200031I-HHSN26100004
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Arizona, doing business as the Arizona Board of Regents. The $151,603.00 delivery order supports the "UNIVERSITY OF CALIFORNIA AT IRVINE CLINICAL TRIAL SUPPORT" effort under the Cancer Prevention Agent Development Program 2012-2017, a major NCI program focused on early-phase clinical cancer research. This contract does not have a set-aside designation. The University of Arizona, as a public research university, 1862 land grant institution, and Hispanic Serving Institution, has extensive capabilities in biomedical sciences, astrophysics, environmental health, and other technical disciplines to support federal research and development activities through contracts and grants. This award reflects the University's expertise in delivering services such as scientific research, data analysis, and educational programming to advance agency missions and scientific knowledge.
University Of Arizona
$151.6k
7/15/14
3/14/15
10/14/14
Delivery Order HHSN261201200031I-HHSN26100010
R & D- CORE INFRASTRUCTURE SUPPORT
University Of Arizona
$2.9m
9/24/15
9/23/19
3/21/23
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
Cancer Prevention Agent Development Program: Early Phase Clinical Research
Added: Mar 04, 2011 8:50 am Pre-Solicitation Request for Proposals (RFP) N01CN05014-69, Cancer Prevention Agent Development Program: Early Phase Clinical ResearchContracting Office AddressDepartment of Health and Human Services, National Institutes of Health (NIH), National Cancer Institute (NCI), Office of Acquisitions, 6120 Executive Boulevard, Suite 600, Room 6002, Bethesda, MD 20892-7195.Note: This synopsis follows a Sources Sought notice that was released on February 12, 2010 under HHS-NIH-NCI-PCPSB-5014-29DescriptionThe National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Prevention (DCP), Phase I/II Cancer Prevention Clinical Trials Program is seeking proposals from qualified organizations who have the capacity to conduct early phase clinical trials and accrue a specified number of subjects per year.The main objective of the contracts awarded as a result of the solicitation will be the conduct of multiple early phase clinical trials to rapidly evaluate the clinical activity and biologic effects of cancer preventive agents. The contracts will provide essential clinical trials infrastructure and laboratory support: (1) To efficiently design and conduct early phase clinical trials of cancer preventive agents of various classes; (2) To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis and correlate these effects with clinically relevant endpoints; and (3) To develop scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response. Each Contractor shall be able to initiate multiple clinical trials per year accruing a minimum of 75 total study participants to Phase 0 - Phase II clinical trials, with the emphasis on Phase II trials. The agents to be studied will be DCP-specified cancer preventive agents as well as agents obtained by the Contractor. The size of each trial will vary depending on phase of development and organ site. However, each Contractor shall have the capacity to perform studies in multiple organs (i.e., more than 2) and is strongly encouraged to establish an infrastructure composed of one or more collaborating institutions to enhance their capability to conduct these clinical trials and to provide specific technical expertise for biomarker studies.The proposed acquisition will be a full and open competition. The contracts for the project are currently held by: Institution and Contract Number-University of Arizona, Tucson, AZ N01-CN-35158University of California-Irvine, Orange, CA N01-CN-35160Northwestern University, Chicago, IL N01-CN-35157Mayo Clinic Foundation, Rochester, MN N01-CN-35000University of Texas M. D. Anderson Cancer Center, Houston, TX N01-CN-35159University of Wisconsin-Madison, Madison, WI N01-CN-35153The North American Industry Classification System (NAICS) code is 541712. The NCI intends to award multiple cost reimbursement type contracts for a base period of five years plus two, one year options on or about June 2012. Request for Proposal number N01CN05014-69 will be available on or about March 21, 2011, with a due date for receipt of proposals on or about July 21, 2011.POTENTIAL OFFERORS WILL BE RESPONSIBLE FOR DOWNLOADING THEIR OWN COPY OF THE SOLICITATION AND AMENDMENTS. ALL INQUIRIES SHALL BE SUBMITTED ELECTRONICALLY TO THE CONTRACTING OFFICER LISTED AS THE POINT OF CONTRACT HEREIN.
N01CN05014-69
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
3/4/11, 8:50 AM